British pharmaceutical company AstraZeneca has floated fresh reviews for its potential Covid-19 vaccine, media reports said.
AstraZeneca, told the media, “We confirm the MHRA’s (Medicines and Healthcare Products Regulatory Agency) rolling review of our potential COVID-19 vaccine. The COVID-19 experimental vaccine produces an immune response in both old and young adults. The vaccine also triggers lower adverse responses among the elderly. In rolling reviews, regulators are able to see clinical data in real time and have dialogue with drug makers on manufacturing processes and trials to accelerate the approval process. The approach is designed to speed up evaluations of promising drugs or vaccines during a public health emergency.”
It is reported that AstraZeneca is developing a vaccine in partnership with the University of Oxford. Furthermore, the government of the UK’s MHRA has also reviewed a vaccine candidate from US-based company Pfizer.
Both AstraZeneca and Pfizer are the companies that are leading the pact to produce a vaccine for the virus. Johnson & Johnson and Moderna are also in the race. It is reported that the vaccine candidates of the companies are in late-stage trials.
The University of Oxford’s ChAdOx1 nCoV-19, the viral vector vaccine clinical trial which embarked in January has been developed from a weakened version of a common cold virus that causes infections in chimpanzees.
The covid-19 has walloped global economies and has taken the lives of 1.19 million people. The pandemic’s threat is not over until a proper vaccine is rolled out.